Deep Intelligence Across Industries

Company Headquarters: Sweden Founded: 1994 Workforce: ~400 Company Working: Vitrolife is renowned as one of the leading providers of IVF laboratories with high-quality products. It offers a broad range of products for the preparation, cultivation, and storage of human cells, tissues, and organs which include needles, pipettes, incubators, and laser & imaging systems, among others. It operates through four business units including media, time-lapse, disposable devices, and art equipment. It runs production facilities in over ten countries worldwide.

Company Headquarters: Humlebaek, Denmark Founded: 1954 Workforce: ~11,000 Company Working: Coloplast Corp. (Coloplast) is a medical device company that develops and markets healthcare products and services across the world. The company functions through three operating segments, namely, chronic care, interventional urology, and wound and skin care. It provides medical devices for ostomy care, continence care products, wound care products, and products for the surgical treatment of urological and gynecological disorders. Coloplast markets and sells its products and services globally. Products are supplied to hospitals, institutions as well as wholesalers, distributors, and pharmacies. In selected markets, it is also a direct supplier to users. It has wholly-owned sales subsidiaries in its principal markets and employed about 12,000 people at the end of 2018.

Company Headquarters: Founded: 1998 Workforce: 377,000 Company Working: Siemens Healthcare Private Limited is the distinctly managed healthcare business of Siemens AG empowering healthcare providers globally to meet their current challenges and to outperform in their respective environments. Siemens is a leader in medical technology. It is continuously updating its portfolio of products and services in its core areas of diagnostic and therapeutic imaging in laboratory diagnostics and molecular medicine. It is dynamically developing its digital health and enterprise services.

Company Headquarters: New Jersey, US Founded: 1990 Workforce: ~46,000 Company Working: Quest Diagnostics is one of the leading providers of pre-employment drugs-of-abuse screening and risk assessment services for the employers and life insurance industry. It offers physicians a vast test menu and develops new innovative tests. The company majorly provides services in the field of cancer diagnostics, anatomic pathology services, and interpretive consultation. It has two segments, namely, diagnostic information services business (DIS) and diagnostic solutions (DS). The DIS segment complies with about 95% of the net revenue. It serves in the US and selected locations outside the US, such as Mexico, the UK, and India.

Company Headquarters: North Carolina, US Founded: 1978 Workforce: ~70,000+ Company Working: Laboratory Corporation of America Holdings (LabCorp) operates worldwide as an independent clinical laboratory company. It operates through two segments, namely, LabCorp Diagnostics and Covance Drug Development. The company’s product & service portfolio comprises a wide range of clinical laboratory tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, hemoglobin A1C, prostate-specific antigen, tests for sexually transmitted diseases, hepatitis C tests, vitamin D, microbiology cultures & procedures, and alcohol & other substance-abuse tests. It also offers services to hospitals, physicians, and other healthcare providers and commercial clients to assist in diagnosing, monitoring, and treating diseases and medical conditions by examining substances in the blood, tissues, and other specimens.

Company Headquarters: Loos, France Founded: 1999 Workforce: ~170 Company Working: GENFIT is a late-stage biopharmaceutical company dedicated to the discovery and development of innovative therapeutic and diagnostic solutions in metabolic and liver-related diseases. The company is currently developing a non-invasive and easy-to-access blood-based IVD test to identify patients with NASH. Also, the company’s pipeline drug, Elafibranor is assessed under phase III clinical trial as a potential treatment for NASH. The company operates in only one segment, the research & development of innovative medicines. The company has its operational facilities in Lille and Paris, France, and Cambridge, Massachusetts, US.

Liberty Mutual occupies a distinctive position: it is simultaneously a top-five US personal-lines carrier and a top-tier global commercial and specialty (re)insurer, funded by permanent mutual capital and a $121 billion investment portfolio managed in-house. That breadth is both its moat and its burden. The personal-lines franchise (Liberty Mutual, Safeco, State Auto, Comparion) gives scale, brand and cash generation; the commercial franchise (Global Risk Solutions, Ironshore, Liberty Specialty Markets, Liberty Mutual Reinsurance, Global Surety) gives cycle diversification and access to hard specialty markets; and Liberty Mutual Investments supplies a private-capital earnings stream that few P&C peers can replicate at this scale. The group has spent three years narrowing rather than broadening: exiting Brazil, the Andes, Western Europe, Northern Ireland, Thailand and Vietnam, shrinking US auto, and rebuilding underwriting discipline. FY2025's record 88.4% combined ratio and $6.8 billion net income validate the strategy. The open question is whether it can now grow again without re-importing the volatility it just removed. Liberty Mutual is a Boston-headquartered, policyholder-owned property and casualty (P&C) insurance group that ranks among the ten largest P&C insurers in the world by gross written premium and among the top ten US personal-auto and homeowners writers. It is structurally unusual for an institution of its scale: because it is organised as a Massachusetts mutual holding company, it has no shareholders, no listed equity, no share price, no earnings per share and no market capitalisation. Its "owners" are the members — the named insureds on in-force policies issued by eight designated Member Companies — whose rights are limited to voting for directors, participating in any distribution on liquidation or demutualisation, and receiving member dividends if declared. Capital is therefore raised only through retained earnings (unassigned equity), surplus notes and senior/junior subordinated debt issued by the intermediate holding company, Liberty Mutual Group Inc. ("LMGI"). This gives management an unusually long planning horizon and insulates it from quarterly equity-market pressure, but it also caps the speed at which the group can grow surplus and makes debt capacity, statutory surplus and rating-agency capital adequacy the binding constraints on strategy. Over 2023–2025 the group executed one of the largest underwriting turnarounds in the US market, moving from a 102.7% combined ratio in FY2023 to 88.4% in FY2025 while shrinking the top line by roughly $2.9 billion — a deliberate trade of volume for profit that management summarises in the internal mantra "integrity, profit, then growth." --- **The company's own description (Q4 2025 earnings release, "About Liberty Mutual Insurance"):** "At Liberty Mutual, we believe progress happens when people feel secure. For more than 110 years we have helped people and businesses embrace today and confidently pursue tomorrow by providing protection for the unexpected and delivering it with care. A Fortune 100 company with more than 40,000 employees in 27 countries and economies, we are the ninth largest global property and casualty insurer and generate more than $50 billion in annual consolidated revenue. We operate through three strategic business units: US Retail Markets… Global Risk Solutions… and Liberty Mutual Investments, deploying more than $100 billion of long-term capital globally across its integrated platform." **Independent characterisation.** Liberty Mutual is best understood as three financially interlocking businesses under one mutual capital structure. The first is a US retail underwriting utility. US Retail Markets (USRM) produced $26.5 billion of net written premium and $29.4 billion of revenue in FY2025. It sells personal auto, homeowners, renters and related coverages to individuals, plus small commercial lines to small businesses. Distribution is deliberately multi-channel and channel-conflicted by design: approximately 1,165 licensed employee "Comparion" agents, 1,063 licensed telesales counsellors, independent agents (principally under the Safeco and State Auto brands), third-party producers, direct online, and sponsored affinity groups. Economics are classic short-tail personal lines — high frequency, rapid repricing, heavy advertising intensity, and a loss ratio that responds within four to six quarters to rate and underwriting actions. The second is a global commercial and specialty (re)insurer. Global Risk Solutions (GRS) wrote $17.2 billion of net premium and generated $19.2 billion of revenue in FY2025 across five market segments: North America, Liberty International Insurance, Liberty Mutual Reinsurance, Global Surety and Other GRS. This business is broker-intermediated, longer-tail, more cyclical in pricing, and materially more exposed to social inflation and reserve risk. It is where the group's Lloyd's platform, wholesale excess-and-surplus capability (Ironshore) and global surety franchise sit. The third is Liberty Mutual Investments (LMI), an in-house asset manager deploying more than $100 billion of general-account capital. LMI is not merely a treasury function: limited-partnership income alone contributed $2,161 million of pre-tax operating income in FY2025 (FY2024: $1,266 million), equal to roughly 22% of consolidated pre-tax operating income. LMI's private-equity, real-estate, private-credit and energy-transition portfolios are a genuine differentiator against listed peers whose boards constrain alternatives allocations. **Revenue model.** Revenue is overwhelmingly insurance premium plus investment return, not product, subscription or licensing. FY2025 revenue decomposed as: premiums earned $44,213 million (87.6%); net investment income $6,075 million (12.0%); fee and other revenues $1,033 million (2.0%); net realised losses $(856) million (−1.7%). Fee revenue is small and derives principally from partner-carrier referral programmes and servicing-carrier work for involuntary assigned-risk pools, self-insured customers and risk retention groups. **Value-chain position.** Liberty Mutual is a risk-bearing balance sheet that also owns distribution (Comparion, telesales, direct), claims handling, risk engineering and loss prevention, and asset management. It is a net buyer of reinsurance ($8,386 million ceded in FY2025) and, through Liberty Mutual Reinsurance, also a seller of reinsurance ($3,920 million assumed). It is a servicing carrier for state involuntary pools, which is why $3,056 million of gross reinsurance recoverables sit against state-mandated pools carrying no direct underwriting risk. **Customer types and end-markets.** Individuals and households (auto, home, renters); small businesses (BOP, workers compensation, commercial auto, general liability); mid-size and large corporates and multinationals (property, casualty, specialty, marine, energy, construction, aviation, D&O, E&O, trade credit, cyber); contractors, developers and public authorities (surety); other insurers and reinsurers (assumed reinsurance); and, through a global inland-marine programme, wireless-handset protection at consumer scale.

Company Headquarters: Minnetonka, MN, US Founded: 1977 Workforce: ~10,001 Company Working: United Healthcare Services Inc. is a part of the UnitedHealth Group. The company has various insurance plans which include Medicare plan, small business plans, individual & business plans, dental plans, short term health insurance, and Medicaid plans. Additional insurance plans of the company include vision insurance, term life insurance, accident insurance, hospitalization insurance, and others.

Company Headquarters: Switzerland Founded: 1872 Workforce: 54,000 Company Working: Zurich is one of the leading multi-line insurer providers in global and local markets. The company provides a broad range of life insurance products and services for property and casualty in more than 210 countries and regions. The key customers for Zurich’s services include small businesses, individuals, and mid-sized and big companies, as well as multinational corporations.

Company Headquarters: New York Founded: 1868 Workforce: ~10,001 Company Working: MetLife Services and Solutions, LLC (MetLife), is one of the largest life insurance companies in the world. It is the global provider of life insurance, employee benefits, annuities, and asset management services to its clients. MetLife serves approximately 100 million customers across 50 countries. The company holds leading market positions in various countries that include the US, Latin America, Japan, Asia, Europe, and the Middle East.

Company Headquarters: Columbus, GA Founded: 1955 Workforce: ~10,001 Company Working: Aflac Incorporated is a wide-ranging business holding company that provides supplemental insurance to individuals in the US and Japan. Aflac's products include critical illness insurance, vision insurance, life insurance, hospital insurance, short term disability insurance, accident insurance, cancer insurance, and fixed-benefit dental plans. The company has a number of subsidiaries, namely, AFLAC Insurance Services Company Limited, Continental American Insurance Company, Inc., American Family Life Assurance Co. of Columbus (Aflac), American Family Life Assurance Company of New York, and others through which it operates its business.

Company Headquarters: Canada Founded: 1865 Workforce: ~37,000 Company Working: Sun Life Financial is a leading financial services organization that provides a wide range of health insurance, wealth, and asset management solutions to its corporate clients and individuals across the globe. Sun Life Financial helps people to achieve lifetime financial security and live healthier lives. The company has offices in 26 countries, with 112,800 advisors across the world. Sun Life Financials operates in Canada, the US, the UK, Ireland, Hong Kong, the Philippines, Indonesia, Japan, India, Singapore, China, Australia, Vietnam, Malaysia, and Bermuda

Company Headquarters: Paris, France Founded: 1816 Workforce: ~104,065 Company Working: AXA is engaged in global insurance, investment management, and other financial services. The company operates in five major segments, namely, life & savings, property & casualty, health, asset management, and banking. It operates in more than 61 countries globally. As of December 2018, the company had 105 million customers globally.

Company Headquarters: The Hague, Netherlands Founded: 1983 Workforce: ~26,543 Company Working: Aegon is multinational life insurance, pensions, and asset management company headquartered in the Netherlands. The company is also active in accident, supplemental health insurance, and general insurance. It operates in three business segments, namely, premium, investment, and fee and commission. It operates in more than 20 countries globally. As of December 2018, the company had 28.5 million customers across the globe.

Company Headquarters: London, UK Founded: 1848 Workforce: ~23,792 Company Working: Prudential is a British multinational company that provides insurance and investment products and services. Some of the insurance products provided by the company include life, accident and health, and property and casualty, as well as fixed and variable annuities. The services provided by the company include personal and group pensions, equity plans, mortgages, and deposit accounts. It has 26 million customers globally. Prudential Corporation Asia, a subsidiary of Prudential, leads insurance and asset management operations across 14 countries in Asia. Jackson National Life Insurance Company, a subsidiary of Prudential, provides life insurance in the US. It has its presence in North America, Europe, Africa, and Asia-Pacific.

Company Headquarters: Beijing, China Founded: 1949 Workforce: ~100,000 Company Working: China Life Insurance Company is a leading life insurance company in China. The company has four major operating segments as life insurance business (Life), health insurance business (Health), accident insurance business (Accident), and others. Its products and services include individual life insurance, group life insurance, and accident and health insurance. It also provides individual and group life insurance, annuity products, and accident and health insurance in China. The company had about 285 million long-term individual and group life insurance policies, annuity contracts, and long-term health insurance policies in force, as of December 2018. The company offers insurance services to more than 500 million customers.

Aurobindo Pharma is India's most US-exposed large-cap generics manufacturer and one of the most vertically integrated generic drug companies anywhere. Its value chain runs from fermentation-based key starting materials, including India's largest Penicillin-G plant at Kakinada, through APIs to finished dosages sold in more than 150 countries. The company had 599 cumulative USFDA ANDA approvals as of October 2026, a figure that includes tentative approvals, and it is one of the largest suppliers of generic prescriptions in the US by volume. Its European formulations business crossed EUR 1 bn in revenue in FY26. The investment debate centres on three things: - whether Aurobindo can convert scale-driven volume leadership into a higher-margin mix of injectables, biosimilars and complex generics; - whether it can expand onshore US manufacturing (Lannett, Raleigh, Dayton); - whether it can contain repeated USFDA compliance issues at its Eugia sterile sites. FY26 revenue was INR 33,653 Cr with a 20.4% EBITDA margin. That trails peers such as Sun Pharma, which earns about 30%. The gap reflects the company's commodity-heavy mix, and it is also the main source of potential upside if mix shift succeeds. --- ### Company self-description In its standard boilerplate on press releases (Q1 FY27 press release, 5 Aug 2026), Aurobindo describes itself as an integrated global pharmaceutical company headquartered in Hyderabad. It says it develops, manufactures and commercialises a wide range of generic pharmaceuticals, branded specialty pharmaceuticals and APIs in more than 150 countries. It cites more than 30 manufacturing and packaging facilities approved by regulators including the USFDA, UK MHRA, EDQM, Japan PMDA, WHO, Health Canada, South Africa's regulator and Brazil's ANVISA. Aggregators citing its annual report summarise the principal activity as manufacturing and marketing APIs, generic pharmaceuticals and related services. ### Independent characterisation Aurobindo is a scale generic manufacturer with four distinguishing features. 1. **Vertical integration.** The company is backward-integrated from fermentation: Pen-G, 6-APA and 7-ACA at Lyfius. It then moves through APIs at Apitoria and into finished dosages. In betalactam antibiotics, this gives it structural cost leadership and protection from Chinese supply disruption. 2. **US volume leadership in oral solids.** This is a low-price, high-volume franchise. The company is now augmenting it with onshore capacity: - Lannett in Seymour, Indiana, with roughly 4 bn doses of annual capacity; - Aurolife in Raleigh, North Carolina; - a newer facility in Dayton, New Jersey. 3. **Diversification away from the US.** Europe is now about a third of revenue, after a string of acquisitions between 2014 and 2019: Actavis Western Europe, Generis and Apotex Europe. Growth Markets and ARV tenders add further spread. 4. **Optionality in specialty businesses.** Eugia covers injectables, oncology, hormonals and peptides. CuraTeQ covers biosimilars, with filgrastim, pegfilgrastim, trastuzumab and bevacizumab approved in various markets and denosumab and omalizumab in late-stage development. ### Revenue model | Revenue type | Approximate share | Comment | |---|---|---| | Product sales: formulations | About 88% (Q1 FY27) | Generic Rx, specialty injectables, OTC, ARV tenders, biosimilars | | Product sales: API | About 11.5-14% | External API sales; Pen-G external sales were INR 100 Cr in Q4 FY26 (ICICI Securities note) | | Services and CDMO | Not separately disclosed | Lannett brings a "growing CDMO business" (deal announcement, July 2025) | | Licensing and royalties | Not separately disclosed | Immaterial on available disclosure | | Subscription | None | n/a | Almost all revenue is product revenue: sales of finished formulations and APIs. The disclosed mix is: - formulations, 88.5% of Q1 FY27 revenue (INR 8,101 Cr of INR 9,150 Cr); - API, 11.5%. ### Value-chain position, customers and end-markets **Upstream:** fermentation KSMs and intermediates (Lyfius), plus APIs (Apitoria, with multiple units at Parawada and elsewhere in Andhra Pradesh and Telangana). **Midstream:** finished-dose manufacturing in India (APL Healthcare, Eugia), the US (Aurolife Raleigh, Dayton, Lannett Seymour), Europe (Portugal and others) and China (Luoxin Aurovitas JV, now 50%). **Downstream customers:** - US wholesalers, group purchasing organisations and retail pharmacy chains; - European tender payers and pharmacies; - global health procurement bodies for ARVs (PEPFAR- and Global Fund-linked tenders); - emerging-market distributors; - Indian prescribers through Auropharm's branded generics. **End-markets:** the US (41.2% of Q1 FY27 revenue), Europe (32.1%), Growth Markets (11.6%), ARV (3.6%) and API (11.5%), all per the Q1 FY27 press release.

Allianz SE is the largest European insurance group by market capitalization and one of the two or three most consequential composite insurance-and-asset-management franchises in the world. It operates a three-engine model — Property-Casualty underwriting, Life/Health protection and retirement, and third-party asset management through PIMCO and Allianz Global Investors — that produced EUR 186.9bn of total business volume and EUR 17.4bn of operating profit in FY2025 across roughly 70 countries and 97 million customers. The strategic distinction is not scale alone but the balance of the three engines: P&C supplies underwriting cash and pricing power, Life/Health supplies a EUR 55.7bn contractual service margin that converts into decades of predictable release, and asset management supplies a capital-light EUR 2.16 trillion fee pool. Allianz has been Interbrand's number one global insurance brand for seven consecutive years, carries AA/Aa2 financial strength ratings, and closed FY2025 with a 218% Solvency II ratio — among the strongest in the peer group. | Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | |---|---|---|---|---|---| | Employees at December 31 | 155411 | 159253 | 157883 | 156626 | 156875 | *Source: Allianz Group key indicators page, updated May 7, 2026.* Headcount peaked in FY2022 and has since been essentially flat, declining 1.5% from the FY2022 peak while operating profit rose 25.8% over the same window — the clearest single expression of the productivity agenda. ### Market capitalization and share data (current) | Metric | Value | As of | |---|---|---| | Share price (XETRA close) | 450.90 | September 1, 2026 | | 52-week high | 453.40 | September 2026 | | 52-week low | 338.80 | trailing twelve months | | Shares outstanding (approx.) | 379.3 million | August 2026 | | Market capitalization | ~171 billion EUR *(derived: price × shares)* | early September 2026 | | Market capitalization per company disclosure | 157.5 billion EUR | June 30, 2026 | | Year-to-date share price gain 2026 | ~15% | September 1, 2026 | | 50-day moving average | 429.93 | September 1, 2026 | | 200-day moving average | 389.44 | September 1, 2026 | --- ### The company's own characterization In the standard boilerplate appended to every FY2025 and FY2026 media release, Allianz describes itself as "one of the world's leading insurers and asset managers, active in almost 70 countries and serving around 97 million private and corporate customers," offering "a broad range of personal and corporate insurance services, including property, life and health insurance, as well as assistance services, credit and global business insurance." It describes its success as "built on technology-enabled customer centricity — providing peace of mind, protection, and prevention." It positions itself as "one of the world's largest investors, managing around 791 billion euros on behalf of our insurance customers" (as of June 30, 2026), with PIMCO and Allianz Global Investors managing "about 2.2 trillion euros of third-party assets." ### Independent characterization Allianz is best understood as three distinct businesses sharing a brand, a balance sheet, a capital-allocation function and a distribution estate. **Engine one — Property-Casualty underwriting.** This is a risk-transfer business monetized through the underwriting margin (premiums minus claims minus expenses) plus the investment return on float. In FY2025 it produced EUR 86.7bn of business volume, a 92.2% combined ratio and EUR 8,992mn of operating profit — 51.8% of total segment operating profit. It splits into retail (including SME and fleet) and commercial (large corporate, MidCorp, credit insurance, internal and third-party reinsurance). Retail is the higher-growth, higher-frequency, lower-severity book; commercial is cyclical, capital-intensive and currently in a softening rate environment. **Engine two — Life/Health.** Under IFRS 17 this is not a premium business but a margin-release business. The economically meaningful metrics are the contractual service margin (EUR 55.7bn at end-2025; EUR 57.3bn at June 30, 2026), the value of new business (EUR 4,829mn FY2025) and the new business margin (5.7% FY2025). Allianz has deliberately rotated the book away from spread-based guaranteed savings toward "preferred lines" — capital-efficient products, unit-linked without guarantees, and protection and health — which represented 91% of FY2025 new business premiums. This is a deliberate reduction of interest-rate and longevity balance-sheet risk in exchange for lower nominal volume. **Engine three — Asset Management.** A capital-light, fee-based business: PIMCO (fixed income, credit, alternatives, based in Newport Beach) and Allianz Global Investors (multi-asset, equities, private markets, based in Frankfurt/Munich/London). Revenue is a basis-point charge on average third-party assets under management plus performance fees. FY2025: EUR 8.5bn operating revenues, EUR 3,345mn operating profit, 60.7% cost-income ratio, EUR 139.3bn of third-party net inflows and EUR 1.990 trillion of third-party AuM. By June 30, 2026 third-party AuM had reached EUR 2.161 trillion. **Engine zero — Corporate and Other.** Group treasury, holding-company financing, banking and alternative-investment activities. Structurally loss-making at the operating line (EUR -168mn in 6M 2026) because it carries the group's debt service and central costs. ### Revenue model mix | Revenue type | Mechanism | FY2025 scale | |---|---|---| | Insurance underwriting margin | Premium less claims less expense, plus reserve run-off | P/C combined ratio 92.2%, i.e. 7.8 points of underwriting margin on earned premium | | Investment return on float and own funds | Yield on ~791bn EUR of insurance assets | Embedded in segment operating investment results | | CSM release (Life/Health) | Amortization of unearned profit on in-force contracts | 55.7bn EUR CSM stock at end-2025 | | Asset management fees | Basis points on 1.99tn EUR third-party AuM plus performance fees | 8.5bn EUR operating revenues | | Fee and commission income | Assistance, credit-risk services, fronting, captives | Not separately disclosed at group level | Allianz has essentially no product-sale, licensing or subscription revenue. The revenue model is: ### Value chain position Allianz occupies risk-bearing (balance sheet), distribution (tied agents, brokers, bancassurance, direct) and manufacturing (product design, actuarial, claims) positions simultaneously. Its integrated position is unusual: unlike pure-play carriers it also controls large distribution assets, and unlike distribution-led aggregators it controls the underwriting balance sheet. The reported interest in acquiring the AA in the UK is a direct expression of a strategy to acquire membership-based distribution rather than more underwriting capacity. ### Customer types and end-markets **Retail individuals:** motor, home, travel, accident, health, life, savings, retirement. **SME and fleet:** commercial property, liability, motor fleet, business interruption. **Large corporates and multinationals:** via Allianz Commercial (formerly AGCS), covering marine, aviation, energy, cyber, D&O, construction, entertainment. **Trade counterparties:** Allianz Trade (formerly Euler Hermes) credit insurance, surety and bonding. **Institutional asset owners:** pension funds, sovereign wealth funds, insurers, endowments (PIMCO, AllianzGI). **Retail fund investors:** mutual funds, ETFs, unit-linked wrappers. **Distribution partners:** banks (HSBC, UniCredit historically, UOB), automotive OEMs (BMW, MINI, Mercedes-Benz, Volkswagen Group UK), MGAs (Ticker in UK), retailers and travel operators via Allianz Partners.

Company Headquarters: London, UK Founded: 2000 Workforce: ~31,323 Company Working: Aviva is a leading international saving, retirement, and insurance business. In the UK, it is the largest general insurer and a leading life and pensions provider. The company operates through three primary areas, namely, life business, general insurance and health, and fund management. It serves 33 million customers across 16 countries, globally. Geographically, it operates in regions such as North America, Europe, and Asia.

Company Headquarters: Shenzhen, China Founded: 1988 Workforce: ~ 376,900 Company Working: Ping An Insurance is one of China’s financial service groups with the most comprehensive range of financial business licenses. The company operates through seven reportable segments, namely, the life and health insurance, property and casualty insurance, banking, trust, securities, other asset management segments, fintech & healthtech, and other businesses. Some of the key subsidiaries of the company include Ping An Life, Ping An Property & Casualty, Ping An Annuity, Ping An Health, Ping An Bank, Ping An Trust, Ping An Securities, and Ping An-UOB Fund. As of June 2017, its online user base has grown to about 403 million users, up by 16.4% from the beginning of the year.

Ontex is a mid-sized European manufacturer of disposable personal hygiene products — adult incontinence, baby diapers and pants, and feminine care — sold predominantly under retailers' own labels and to healthcare channels, with a small portfolio of owned healthcare brands. After a four-year portfolio clean-up that sold all Emerging Markets operations (Mexico, Algeria, Pakistan, Brazil, Turkey), the group now generates ~€1.74bn of revenue from Europe and North America. Adult care has become the largest category (~47% of revenue in FY2025) and the designated growth pillar, while baby care — historically the core — is under structural pressure from falling birth rates, A-brand promotional intensity and retailer-brand share loss. The company is in a second-phase turnaround under CEO Laurent Nielly (since January 2026): a €240m "Focus to Value" savings programme, a profitability-first reset in North America, €144m of impairments, and a new CFO. With leverage at ~3.2x, bonds trading near 87% of par and Russia (≈5% of revenue) placed under Kremlin interim administration in October 2026, Ontex is a stressed small-cap equity whose value hinges on execution. --- ### Company's own description Ontex describes itself (H1 2026 press release, Jul 2026) as a leading international developer and producer of baby care, feminine care and adult care products, serving both retailers and healthcare, primarily in Europe and North America. Its corporate website adds that it partners with retailers and healthcare providers and is trusted by over 35 million people (ontex.com, 2026). ### What the company does Ontex designs, develops and manufactures absorbent hygiene products (AHPs) on high-speed converting lines that combine fluff pulp, superabsorbent polymer (SAP), nonwovens, films, elastics and adhesives. Its three categories are: **Adult care (incontinence):** light incontinence pads, medium/heavy incontinence briefs (all-in-ones), pull-up pants, underpads and related products, sold to (a) healthcare channels — hospitals, nursing homes, home-care distributors and reimbursed tender systems in several European countries — and (b) retail (retailer-brand pads and pants). Adult care revenue was €814.1m in FY2025 (+1.6% LFL). **Baby care:** baby diapers (tape), baby pants (pull-ups) and, historically, wipes; sold mainly as retailer brands across Europe and North America and as contract manufacturing for third parties in North America. Revenue €696.6m in FY2025 (−11% LFL). **Feminine care:** sanitary towels, pantyliners and tampons, predominantly retailer brands in Europe plus contract manufacturing. Revenue €228.2m in FY2025 (−3.3% LFL). (Source: Ontex FY2025 results press release, 12 Feb 2026.) ### Business model and revenue model | Dimension | Characterization | |---|---| | Revenue model | ~100% product sales. No material service, subscription or licensing revenue disclosed | | Channel model | (1) Retailer brands (private label) — Ontex manufactures to retailer specification, often under multi-year supply contracts won through tenders; (2) Healthcare — owned brands and tender supply into institutional and reimbursed channels; (3) Contract manufacturing — production for other brand owners, around one-third of North American revenue (FY2025 results presentation) | | Value chain position | Mid-stream converter: buys commodity/semi-specialty inputs (pulp, SAP, polypropylene nonwovens, films) and converts them into finished goods; it does not own retail distribution (except healthcare logistics in some markets) | | Pricing dynamic | Contracted or index-linked pricing with retailers; pass-through lags input-cost moves by one or more quarters (illustrated in H1 2026, when oil-derivative and freight costs rose faster than pricing actions) | | Cost structure | Raw materials are the largest cost block; fixed-cost absorption is significant, so volume swings drive outsized margin moves (FY2025: −5% volume drove a 2pp adj. EBITDA margin contraction) | ### Customers and end-markets **Customer types:** large grocery and discount retailers and drugstore chains in Europe (named customers not disclosed), large US retailers (not named), healthcare providers and distributors, public tender bodies, and third-party brand owners (contract manufacturing). **End-markets:** Western, Central and Eastern Europe (including Russia via a local subsidiary), North America (US, supplied from Stokesdale, North Carolina and Tijuana, Mexico — the latter USMCA-compliant), and selected overseas markets (including Australia via an Eastern Creek plant; "contract exits in other overseas markets" were cited in H1 2026). ### Independent characterization Ontex is a scale private-label converter in a category dominated by global A-brands (P&G, Kimberly-Clark, Essity). Its economic moat is limited to (i) manufacturing cost and quality at scale, (ii) long-standing retailer relationships, (iii) healthcare-channel know-how in adult incontinence, and (iv) innovation speed for retailer brands (e.g., baby pants, skin-health adult products). The business is structurally exposed to: raw-material price volatility; A-brand promotional cycles that compress the price gap with private label; demographic decline in baby care; and customer concentration. The post-divestment Ontex is cleaner but smaller, more levered relative to EBITDA, and now heavily dependent on European adult care for growth.

Bayer is a German life-science group with three businesses: Crop Science, Pharmaceuticals and Consumer Health. It is the world's largest combined seed, trait and crop-protection supplier, a mid-sized prescription-drug maker, and a top-five self-care company. Fiscal 2025 sales were EUR 45.6 billion. The 2018 purchase of Monsanto brought leading corn and soybean genetics but also glyphosate and PCB litigation, which has consumed well over EUR 10 billion in settlements and produced net losses in 2023, 2024 and 2025. Under CEO Bill Anderson the company has cut management layers, held the dividend at the legal minimum, and concentrated on four priorities: rebuilding the pharma pipeline, containing litigation, reducing debt and improving crop profitability. In 2026 a 7–2 U.S. Supreme Court ruling on federal pre-emption and a proposed USD 7.25 billion class settlement moved the litigation closer to resolution, though the settlement still awaits final court approval. --- **Company's own description.** Bayer describes itself as a global enterprise with core competencies in the life-science fields of health care and nutrition, operating under the mission "Health for all, Hunger for none" (Annual Report 2025; press boilerplate 2026). Bayer AG is a holding company; operations sit in subsidiaries worldwide. In fiscal 2025 the Group had about 88,000 employees, sales of EUR 45.6 billion and R&D expenses of EUR 5.8 billion. **Independent characterisation.** Bayer is best understood as three distinct businesses sharing a balance sheet, a brand and a legal liability. Crop Science (47 percent of FY2025 sales) is an input supplier to farmers. It earns money from proprietary seed and biotech traits, from chemical and biological crop protection, and to a small extent from digital farming subscriptions. Seed and trait revenue carries royalty-like economics: Bayer licenses traits to other seed companies, and two licensing settlements with Corteva lifted results in Q4 2025 and Q1 2026. The business is strongly seasonal, with Northern Hemisphere sales concentrated in the first half and Latin American sales in the second. Pharmaceuticals (39 percent of sales) discovers, develops and sells prescription medicines, concentrated in cardiovascular and renal disease, oncology, women's health and ophthalmology, plus a radiology unit selling contrast agents and injector hardware. Revenue is almost entirely product sales, with some licence income (for example U.S. Xarelto royalties from Johnson & Johnson, and Eylea outside the United States under a collaboration with Regeneron). The division is in the middle of a patent transition: Xarelto and Eylea are declining while Nubeqa and Kerendia are growing quickly. Consumer Health (13 percent of sales) sells non-prescription brands through pharmacies, mass retail and e-commerce. It is a branded consumer-goods model with stable margins and low capital intensity. **Revenue model mix.** Bayer does not disclose a product/service/licensing split. On the evidence of the Annual Report 2025, the large majority of revenue is product sales; licensing income is embedded in Crop Science seed and trait lines and in Pharmaceuticals; subscription revenue (Climate FieldView, radiology software) is immaterial at Group level. An exact percentage split is not publicly disclosed. **Value-chain position.** Bayer is a research-based originator and manufacturer. It owns discovery, development, active-ingredient and finished-product manufacturing, and commercial organisations, and sells through distributors, retailers, wholesalers, hospitals and pharmacies rather than directly to end users in most markets. **Customers and end markets.** Farmers, agricultural retailers and distributors, and seed licensees (Crop Science); wholesalers, hospitals, physicians, pharmacy chains, governments and payers (Pharmaceuticals); pharmacies, supermarkets, drugstores and online retailers (Consumer Health).

Amano Enzyme is a family-led, Nagoya-based specialty enzyme manufacturer with 127 years of corporate history and 78 years of enzyme production. It does not compete in bulk commodity enzymes for detergents, biofuels or feed. Its franchise is high-value microbial enzymes for food processing, digestive health and dietary supplements, diagnostics, regenerative medicine and biocatalysis. It has three Japanese plants, a plant in Jiangsu, China, and a manufacturing and blending site in Elgin, Illinois. It combines traditional koji (solid-state) and liquid fermentation with classical strain screening and modern protein engineering. More than 70% of sales come from outside Japan. R&D spending runs at about 10% of sales, supported by roughly 420 patents and a library of about 20,000 microbial strains. The balance sheet is very strong, with an equity ratio near 89% at March 2024. Disclosure is minimal. Growth rests on plant-based protein enzymes and a 2024 push into non-food industrial applications. --- **Company's own description.** The company describes its business as the manufacture and sale of enzyme agents for the pharmaceutical, food and manufacturing industries and for diagnostic reagents, together with pharmaceuticals, veterinary medicines and feed additives (Company Overview; Sustainability Report 2025). Its recruiting materials divide activity into two fields. The medical field covers pharmaceutical, diagnostic and synthesis enzymes. The food field covers enzymes for dairy, seasonings, alcoholic beverages and baking (Mynavi). **Independent characterisation.** Amano is a pure-play specialty enzyme producer and sits mid-value-chain. It sources microbial strains from nature, improves them by classical mutagenesis or, where markets permit, by genetic and protein engineering. It then ferments, purifies, formulates and sells enzyme preparations to industrial customers. It does not sell consumer products. The company once made over-the-counter medicines such as the "Biodiastase" stomach remedy, and it exited that business when it decided in 1996 to specialise in enzymes. **Revenue model.** Revenue is almost entirely product sales of enzyme preparations, sold by weight and activity unit to business customers. The company also offers tailor-made enzyme development with customers ("Tailor-Made Solutions" and the "Enzyme Application Studio"). Whether this generates separate service or licensing revenue is not publicly disclosed. There is no evidence of subscription revenue. The product, service and licensing mix is not publicly disclosed. **Value chain position and customers.** Customers are food and beverage manufacturers, plant-protein ingredient processors, dietary supplement formulators, over-the-counter drug makers, in-vitro diagnostics manufacturers, cell-therapy and regenerative medicine developers, and fine-chemical and pharmaceutical synthesis operations. Japanese recruiting disclosures state that Amano's digestive enzymes hold the leading share in domestic stomach remedies (Mynavi; Plus-H). **End-markets.** The website organises applications under three headings: Food, Healthcare & Medical, and Green Chemistry. A separate microsite, Plants Unlimited, covers plant-based food enzymes. The Sustainability Report 2025 adds prospective fields that the company is exploring: agriculture, energy, materials, textiles and environmental conservation.

Biocatalysts Ltd. is a Welsh specialty enzyme developer and manufacturer and the operating core of BRAIN Biotech AG's BRAINBiocatalysts segment. Founded in 1983, it serves niches the commodity enzyme majors under-serve: flavour and dairy protein modification, plant-based foods, baking, brewing and beverages, pet food, and custom enzymes for life science and pharmaceutical customers. Its model combines a catalogue of branded food enzymes (Promod, Lipomod, Flavorpro, Depol and others) with a fee-for-service enzyme development and manufacturing offer that takes a customer's enzyme from discovery through strain development to commercial fermentation in Cardiff. Since November 2023 it has also owned BRAIN's continental European and US enzyme blending and distribution businesses (Breatec, WeissBioTech, Biosun). The entity is small, with group turnover of GBP 36.2 million in FY2024, and its fortunes are tied to a parent that is loss-making at group level, thinly capitalised and in the middle of a CEO transition. --- **Company's own description.** The company describes itself on its website as a biotechnology company with global reach that produces specialist enzymes at commercial scale for a variety of industries, using its technical, commercial and regulatory capabilities for customers. Its boilerplate adds that it was established in 1983 and has been a member of the BRAIN Biotech Group since 2018. **Independent characterisation.** Biocatalysts Ltd. is a mid-tier specialty enzyme house with three revenue streams. 1. **Catalogue enzyme products.** Branded, off-the-shelf enzyme preparations, mainly proteases, lipases, carbohydrases and flavour enzymes, sold to food, beverage, flavour, nutrition and pet food manufacturers. Sales are transactional, by volume, direct and through distributors. 2. **Custom enzyme development and manufacture.** Fee-based development projects ("Flexible Work Packages" and "Custom Enzyme Development") followed by long-term supply of the resulting enzyme. This stream combines service income during development with product income after scale-up. The life science offering is marketed with the parent as "BRAINBiocatalysts Life Science Solutions" under the line "Your Product | Your IP | Your Future", meaning the customer keeps the intellectual property. 3. **Fermentation services.** Contract microbial fermentation and downstream processing, including large-scale freeze-drying, at the Cardiff site. **Revenue model mix.** The split between product, service and contract manufacturing revenue is not publicly disclosed in the sources consulted. There is no subscription or material licensing revenue at entity level. Royalty-type income sits in the parent's BRAINBioIncubator segment, not in Biocatalysts Ltd. **Value chain position.** The company is a manufacturer and formulator. It sits downstream of enzyme discovery, where it draws on BRAIN Biotech's Zwingenberg research campus and strain libraries, and upstream of food and pharmaceutical processors. Since November 2023 it has also owned blending, application and distribution businesses in the Netherlands, Germany and the United States. **Customer types and end-markets.** The website lists six sectors: Food, Flavors, Life Science, Pharmaceuticals, Industrial Biotech, and Fermentation Services. Customer names and concentration are not publicly disclosed.

GELITA AG is one of the world's two largest producers of collagen proteins — gelatin, collagen peptides and collagen — and the largest family-owned player in an industry otherwise being consolidated by listed conglomerates. Operating from Eberbach since its origins in 1875, the group converts by-products of the meat industry (pig skin, bovine hide, bones) into more than 250 gelatin grades and a branded portfolio of "Bioactive Collagen Peptides" (VERISOL®, FORTIGEL®, FORTIBONE®, BODYBALANCE®, TENDOFORTE®, PeptENDURE®, CURADERM®). It serves confectionery and food manufacturers, softgel and hard-capsule pharmaceutical producers, dietary-supplement brands, and technical/bioscience users, and monetises residual streams as fats, proteins and minerals. Its differentiation rests on clinically substantiated peptide brands, pharma-grade quality systems, a 20-plus-plant global network spanning both porcine and bovine (including halal) raw materials, and in-house research institutes. Its principal strategic challenge is that its leading competitor, Rousselot, is merging with PB Leiner to form a ~USD 1.5 billion collagen company. --- ### What the company does GELITA manufactures collagen-derived proteins from animal by-products sourced from the meat-processing industry. Raw materials (pig skins, bovine hides, bovine bones, and — in some product lines — fish) undergo pre-treatment (acid or alkaline conditioning, demineralisation of bones into ossein), extraction, filtration, concentration, sterilisation and drying. The output streams are: 1. **Gelatin** — partially hydrolysed collagen with gelling, film-forming and binding properties, sold in hundreds of grades by Bloom strength, viscosity, particle size and raw-material origin. 2. **Collagen peptides** — enzymatically hydrolysed collagen with low molecular weight and no gelling, sold both as generic protein and as branded "Bioactive Collagen Peptides" (BCP®) backed by clinical studies. 3. **Collagen** (non- or partly-water-soluble) — referenced by the company as a third category within its range. 4. **Fats, proteins and minerals (FPM)** — co-products such as GELIFAT® (fat, used in biofuel and feed), GELIPRO® (protein for feed) and GELIMIN® (mineral, used in fertiliser and feed). The company's own description, as used on its website, presents GELITA as a family-owned, innovation-driven firm with roughly 20 sites that produces future-oriented collagen-protein ingredients for food, dietary supplements, pharmaceuticals and technical applications, under the mission "Improving Quality of Life" [S2]. Because GELITA publishes no annual report to the public, there is no formal "annual report description" available; the website statement is the closest equivalent. ### Business model and revenue model | Revenue type | Description | Indicative weight | |---|---|---| | Product sales — commodity/standard gelatin | Food, pharma and technical gelatin sold B2B, typically on annual or multi-year supply contracts with price adjustment linked to raw-material and energy costs | Not publicly disclosed (historically the volume backbone) | | Product sales — specialty gelatin | Engineered grades (RXL®, EASYSEAL®, RAPISOL®, DELASOL®, CONFIXX®, SOLUFORM®, MEDELLAPRO®, IMAGEL®) priced at premiums for functional performance | Not publicly disclosed | | Product sales — branded collagen peptides (BCP®) | Branded, clinically substantiated ingredients licensed for on-pack use by supplement brands; higher margin | Not publicly disclosed; company described collagen peptides as a double-digit-growth line [S14] | | Product sales — FPM co-products | Fats, proteins, minerals sold into biofuel, feed and fertiliser markets | Not publicly disclosed | | Consumer products | GELITA Health GmbH markets finished supplements | Not publicly disclosed; small | | Services | Application support, formulation service, contract manufacturing, GELITA Pharma Institute services | Not separately monetised in disclosures | | Licensing | Use of BCP® brand names and claims on customer products is part of the ingredient sale; no stand-alone licensing revenue disclosed | — | There is no subscription revenue. The model is overwhelmingly product-based, with services used to pull through ingredient sales. ### Value-chain position GELITA sits in the midstream of the animal by-product value chain: upstream are slaughterhouses, tanneries and renderers supplying hides, skins and bones; downstream are confectionery, dairy, meat, supplement, capsule and pharmaceutical manufacturers. It does not own slaughter operations (unlike Darling Ingredients, which is vertically integrated into rendering), which makes raw-material procurement a structural strategic priority — the company has historically described pursuing several strategies to secure raw-material supply [S15]. ### Customer types and end-markets The company's website organises its markets into: Food (confectionery, dairy, meat, beverages); Health & Nutrition (beauty, healthy aging, sports nutrition, protein enrichment, sugar reduction); Pharma (hard capsules, softgels, tablets, microencapsulation); Bioscience (vaccine stabilisation, 3D bioprinting, medical devices, cultured meat); Technical (cleaning additives, metalworking fluids, paper coating, biofuel, fertiliser, galvanisation aid, ballistic tissue simulation, art restoration); Photo; Animal Feed; and Pet Health [S8]. ### Independent characterisation GELITA is best understood as a two-speed business: a mature, cyclical, capital-intensive gelatin franchise whose economics are governed by raw-material spreads and energy costs, layered with a faster-growing, higher-margin, science-led collagen-peptide brand portfolio that behaves more like a specialty nutrition ingredients business. The strategic logic since the mid-2010s has been to shift mix toward the second engine (evidenced by the 2017–18 Iowa collagen-peptide expansion, EUR 56 million of 2017 capex mostly directed to capacity, and a steady cadence of BCP® launches) while defending the gelatin base through specialty pharma grades and geographic breadth (halal bovine via SelJel, China via Liaoyuan). As a family-owned company with a modest disclosed credit facility (EUR 100 million), it competes against a much larger, vertically integrated rival with balance-sheet flexibility that GELITA does not appear to have.

| Attribute | Detail | Source / Year | |---|---|---| | Legal name | MERCK Kommanditgesellschaft auf Aktien | AR 2025 | | Common name | Merck KGaA, Darmstadt, Germany | AR 2025 | | US/Canada trade names | MilliporeSigma, EMD Serono, EMD Electronics | AR 2025 | | Former names / predecessor forms | Engel-Apotheke (pharmacy, 1668); E. Merck (family partnership, pre-1995); converted to KGaA with IPO in 1995 | Company history | | Founded | 1668 (Friedrich Jacob Merck acquires the Engel-Apotheke, Darmstadt) | AR 2025 | | Legal form | Kommanditgesellschaft auf Aktien (partnership limited by shares) | AR 2025 | | Incorporation jurisdiction | Germany (commercial register, Darmstadt) | AR 2025 | | Ultimate parent / controlling holder | E. Merck KG, Darmstadt (founding family; 70.274% of total capital as general partner) | AR 2025 | | Free float | 29.726% of total capital; 129.2 million shares | AR 2025 | | Theoretical total shares (for EPS/market cap) | 434.8 million | AR 2025 | | Headquarters | Frankfurter Straße 250, 64293 Darmstadt, Germany | Q1 2026 Financial Statement | | Primary listing | Frankfurt Stock Exchange (Xetra), regulated market; DAX 40 member | AR 2025 | | Ticker | MRK (Xetra); Bloomberg MRK GY; Reuters MRCG; Dow Jones MRK.DE | Q2 2026 press release | | ISIN / WKN | DE0006599905 / 659990 | Q1 2026 Financial Statement | | US OTC instruments | MKKGY (ADR, ISIN US5893392093, i.e. CUSIP 589339209); MKGAF (ordinary shares, OTC) | Market data providers | | CUSIP for ordinary shares | Not applicable (German ISIN-only security) | — | | Fiscal year end | 31 December | AR 2025 | | Employees (31 Dec 2025) | 62,461 | AR 2025 | | Employees (30 Jun 2026) | 62,136 | Q2 2026 press release | | Countries with operations (2025) | 65 | AR 2025 | | Auditor | Deloitte GmbH Wirtschaftsprüfungsgesellschaft, Munich (elected by AGM on 24 April 2026 as auditor and Group auditor for FY2026; Deloitte also signed recent audit opinions — FY2025 auditor identity should be confirmed in the AR 2025 Independent Auditor's Report) | AGM 2026 convening notice | | Market capitalisation (31 Dec 2025) | EUR 53,304 million (at EUR 122.60, 434.8m theoretical shares) | AR 2025 | | Market capitalisation (latest verified) | ~EUR 57.2–57.7 billion at EUR 131.65 (Xetra close, 10 September 2026) | Market data (ftd.de); derived | | Credit ratings | Moody's A3 (stable), S&P A (stable), confirmed November 2025 | AR 2025 | | Websites | emdgroup.com (US/Canada); merckgroup.com (rest of world) | Company | The entity profiled is MERCK Kommanditgesellschaft auf Aktien ("Merck KGaA, Darmstadt, Germany"), the German science and technology group headquartered in Darmstadt. It is a listed public company (DAX 40 constituent), which matches the "Public company" type supplied. It must not be confused with Merck & Co., Inc. (Rahway, New Jersey; "MSD" outside North America), which has been a separate, unrelated company since 1917. In the United States and Canada, Merck KGaA operates as MilliporeSigma (Life Science), EMD Serono (Healthcare) and EMD Electronics (Electronics); the corporate US-facing website is emdgroup.com. | Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | |---|---|---|---|---|---| | Employees at 31 Dec (number) | 60334 | 64232 | 62908 | 62557 | 62461 | Source: AR 2025, Business Development 2021–2025. Headcount at 30 June 2026 was 62,136 (Q2 2026 press release). The three-year trend (FY2023–FY2025) shows a gradual decline of ~0.7% cumulatively, reflecting the Surface Solutions divestment (July 2025) and efficiency measures, partially offset by the SpringWorks acquisition (July 2025). Around 6,500 employees work in R&D and related functions (AR 2025). Merck KGaA is a 358-year-old, family-controlled, diversified science and technology group generating EUR 21.1 billion of net sales (FY2025) across three complementary business sectors: Life Science (42% of sales; a top-three global supplier of research tools, bioprocessing consumables and testing services, known in North America as MilliporeSigma), Healthcare (41%; a specialty pharmaceutical company with established franchises in oncology, multiple sclerosis, fertility and cardiometabolic care plus a new rare-tumour franchise acquired via SpringWorks), and Electronics (17%; a now pure-play semiconductor and optronics materials, equipment and metrology supplier exposed to AI-driven advanced nodes). The group operates at a ~29% EBITDA pre margin with net financial debt of ~1.4x EBITDA pre. Its investment case rests on three growth drivers — Process Solutions, Rare Diseases and Semiconductor Solutions — which management expects to generate up to 80% of medium-term growth, now being reinforced by the pending US$11.3 billion Bio-Techne acquisition. --- ### Company's own description (paraphrased from AR 2025) The company describes itself as a science and technology company guided by the vision "Sparking Discovery, Elevating Humanity," working across Life Science, Healthcare and Electronics to create value for customers and patients. The founding family, now in its 13th generation, remains majority owner through the KGaA structure. Financial reporting presents three business sectors plus Corporate and Other, and five regions (Europe, North America, Asia-Pacific, Latin America, Middle East and Africa). The company's own boilerplate (2026 press releases) characterises its activity as accelerating drug development and manufacturing, discovering treatments for challenging diseases, and enabling "the intelligence of devices." ### Independent characterisation Merck KGaA is best understood as a conglomerate of three high-margin specialty businesses with distinct economic cycles: 1. **Life Science** is a consumables-heavy, recurring-revenue tools franchise. Roughly 42% of sector sales (Process Solutions) are "embedded" in customers' validated biomanufacturing processes (filters, chromatography resins, single-use assemblies, cell culture media, excipients), creating high switching costs because regulatory re-validation is required to change suppliers. The research catalogue business (legacy Sigma-Aldrich; now Discovery Solutions) is a broad, transactional, e-commerce-led reagent business with more than 300,000 products. Services (testing, CDMO for ADCs/viral vectors/HPAPIs) are smaller and lumpier. 2. **Healthcare** is a mid-sized specialty pharma business whose cash generation rests disproportionately on mature, off-patent or near-off-patent brands (Glucophage, Concor, Euthyrox, Erbitux, Rebif, Gonal-f) and on Mavenclad, which began losing US exclusivity in 2026. The SpringWorks acquisition (July 2025) created a Rare Diseases franchise (Ogsiveo, Gomekli/Ezmekly, pimicotinib) intended to offset these erosions. Historically, internal R&D productivity has been weak (late-stage failures of evobrutinib and xevinapant in 2023–2024). 3. **Electronics** is a materials-and-process-solutions supplier to semiconductor fabs (logic, memory, advanced packaging) and display panel makers. Following the Versum Materials (2019) and AZ Electronic Materials (2014) acquisitions and the 2025 divestment of Surface Solutions (pigments), it is positioned as a pure-play electronics business with 72% of sector sales in Asia-Pacific. ### Revenue model mix | Revenue model | Where it sits | Characterisation | Disclosure status | |---|---|---|---| | Product sales — consumables/reagents | Life Science (Process, Discovery, Advanced Solutions) | Recurring, volume-driven; process-embedded in GMP manufacturing | Segment-level only | | Product sales — instruments/equipment | Life Science (lab water, automation), Electronics (DS&S delivery systems, Unity-SC metrology tools) | Capex-cyclical, project-driven | Not separately disclosed | | Product sales — prescription pharmaceuticals | Healthcare | Patent/brand-driven; exposed to pricing, tenders, generics | Product-level sales disclosed | | Product sales — specialty electronic materials | Electronics (Thin Films, Formulations, Specialty Gases, display materials) | Recurring, wafer-start driven; qualified per node | BU-level only | | Services | Life Science Services/Advanced Solutions (contract testing, CDMO), Electronics (MEGASYS gas & chemical services) | Contracted, multi-year in part (e.g. Genetix five-year testing agreement, May 2026) | Not separately disclosed | | Licensing/collaboration income | Healthcare (alliances; collaboration income included in net sales by definition) | Irregular | Not separately disclosed | | Subscription/software | Life Science (Synthia, AIDDISON, ChemisTwin, Athinia/Syntropy data platforms) | Nascent | Not publicly disclosed | The company does not disclose a product/service/subscription/licensing percentage split. Analyst view: product sales (consumables, materials and medicines) constitute the overwhelming majority (>90%) of group revenue; this is an estimate and is flagged as such. ### Value-chain position and customers | Sector | Value-chain position | Customer types | End-markets | |---|---|---|---| | Life Science | Upstream supplier of tools, raw materials and services to drug discovery, development, manufacturing and QC | Academic/government labs, biotech, pharma, CDMOs, diagnostics, industrial/applied labs | Biopharma (mAbs, ADCs, cell & gene therapy, vaccines), academic research, diagnostics, food/environmental testing | | Healthcare | Integrated discovery-to-commercialisation specialty pharma | Prescribers, hospitals, payers, governments, IVF clinics, distributors | Oncology, neurology & immunology, fertility, cardiometabolic/endocrinology, rare tumours | | Electronics | Tier-1 materials, delivery systems, metrology/inspection supplier to fabs and panel makers | Logic foundries, memory makers, OSATs, display panel makers | AI/HPC chips, memory, advanced packaging, displays, AR/VR optics | Regional mix of sector sales (AR 2025): Life Science 71% Europe + North America, 28% Asia-Pacific + Latin America; Healthcare 54% Europe + North America, 39% Asia-Pacific + Latin America; Electronics 72% Asia-Pacific, 26% Europe + North America.

Company Headquarters: Florida, US Founded: 1999 Workforce: ~800 Company Working: Ology Bioservices, Inc. is an integrated biopharmaceutical company that develops and manufactures biopharmaceuticals and medical devices. It specializes in cell therapy, gene therapy, viral vectors, antibodies, oncolytic viruses, biopharmaceutical manufacturing, and vaccines. It has collaboration and partnerships with recognized government agencies, namely the Department of Defense and Medical Countermeasures Advanced Development and Manufacturing, which support it in developing biodefense products. Moreover, it has decades of experience in developing, licensing, and manufacturing proteins, therapeutics, and vaccines. It develops products to offer both commercial customers and US governments. Furthermore, it is a wholly owned company of National Resilience, Inc. (US), and assisting Resilience through its services includes regulatory support from preclinical through licensure and cGMP manufacturing up to biosafety level 3 (BSL3).

Company Headquarters: Lyon, US Founded: 2009 Workforce: ~25 Company Working: Fabentech Biotech is a pharmaceutical company that develops and manufactures polyclonal antibody treatments. Its platform is safe, tested, and fully validated on polyclonal antibody technology for fighting high-priority biological agents that could threaten public health. It has many local, national, and international partners, namely the National Institutes of Health (UK), US Army, World Health Organization, and the European Defense Fund, who are supporting its biodefense product development. This is the only company in Europe that is able to produce biodefense solutions while adhering to the most strict international norms